Nuveen Asset Management LLC Has $12.91 Million Holdings in Cellebrite DI Ltd. (NASDAQ:CLBT)

Nuveen Asset Management LLC increased its holdings in shares of Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 38.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 585,839 shares of the company's stock after buying an additional 162,886 shares during the quarter. Nuveen Asset Management LLC owned 0.28% of Cellebrite DI worth $12,906,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of CLBT. Gen Wealth Partners Inc purchased a new position in Cellebrite DI in the fourth quarter valued at about $85,000. NewEdge Advisors LLC grew its stake in Cellebrite DI by 600.7% in the fourth quarter. NewEdge Advisors LLC now owns 3,910 shares of the company's stock valued at $86,000 after purchasing an additional 3,352 shares in the last quarter. R Squared Ltd purchased a new position in Cellebrite DI in the fourth quarter valued at about $100,000. Polen Capital Management LLC purchased a new position in Cellebrite DI in the fourth quarter valued at about $222,000. Finally, Victory Capital Management Inc. purchased a new position in Cellebrite DI in the fourth quarter valued at about $234,000. Hedge funds and other institutional investors own 45.88% of the company's stock.

Cellebrite DI Stock Performance

Shares of CLBT stock traded down $0.21 during trading hours on Friday, hitting $16.57. The company had a trading volume of 1,831,152 shares, compared to its average volume of 1,461,623. Cellebrite DI Ltd. has a 12 month low of $10.25 and a 12 month high of $26.30. The firm has a market capitalization of $3.97 billion, a price-to-earnings ratio of -11.92, a PEG ratio of 4.27 and a beta of 1.44. The firm's fifty day moving average is $18.65 and its 200 day moving average is $20.13.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last released its quarterly earnings data on Wednesday, May 14th. The company reported $0.10 earnings per share for the quarter, beating the consensus estimate of $0.09 by $0.01. Cellebrite DI had a positive return on equity of 58.70% and a negative net margin of 70.54%. The company had revenue of $107.55 million for the quarter, compared to analyst estimates of $109.36 million. During the same period in the prior year, the company posted $0.08 EPS. The company's revenue was up 20.0% compared to the same quarter last year. On average, sell-side analysts expect that Cellebrite DI Ltd. will post 0.3 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on CLBT shares. Needham & Company LLC lowered their target price on Cellebrite DI from $28.00 to $24.00 and set a "buy" rating on the stock in a research note on Wednesday, May 14th. JPMorgan Chase & Co. reduced their price target on Cellebrite DI from $29.00 to $25.00 and set an "overweight" rating for the company in a research report on Monday, May 12th. Finally, Lake Street Capital boosted their price target on Cellebrite DI from $17.00 to $26.00 and gave the stock a "buy" rating in a research report on Friday, February 14th. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Cellebrite DI currently has an average rating of "Buy" and a consensus price target of $22.43.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.